ValiRx plc (GB:VAL) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ValiRx’s subsidiary, Inaphaea BioLabs, has successfully shipped its first batch of Assay Ready Reagents, marking a significant step in the company’s commercialization efforts. These reagents, derived from a biobank of over 450 patient-derived cells, offer a new revenue stream by allowing customers to conduct assays without in-house cell growth. This milestone highlights ValiRx’s strategic advancement in providing innovative cancer therapeutics and women’s health solutions.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
